Barclays raised the firm’s price target on Nuvalent (NUVL) to $112 from $100 and keeps an Overweight rating on the shares post the Q3 report. The firm says all the company’s catalysts are on track.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent, Inc. Reports Q3 2025 Progress and Financials
- Nuvalent’s Strong Financial Position and Strategic Progress Drive Buy Rating
- Nuvalent reports Q3 EPS ($1.70), consensus ($1.32)
- Nuvalent’s Zidesamtinib Study: A Potential Game-Changer in Cancer Treatment
- Nuvalent’s Promising Phase 3 Study: A Potential Game-Changer in NSCLC Treatment